Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 59

Sort by

Sort Order Select

Journal Articles

Immune Content of Mature and Licensed Cytotoxic Cells Is Associated with Treatment-Free Remission in Chronic Myeloid Leukemia

Camila Araújo Bernardino Garcia, Larissa Sarri Binelli, Leonardo Carvalho Palma, Leticia Olops Marani, Mariana Medeiros, Allana Guimarães de Carvalho, Priscila Santos Scheucher, Josiane Lillian Schiavinato, Pedro Manoel Marques Garibaldi, Robert Welner, Fabíola Attié de Castro, Katia B Pagnano, Lorena Lobo Figueiredo-Pontes

Blood (2024) 144 (Supplement 1): 1756.

https://doi.org/10.1182/blood-2024-208109

Published: 2024

Journal Articles

Impact of the 2022 Who Classification on Chronic Myeloid Leukemia

Estela Gasparotto Emiliano, Gustavo Emmanuel Alves Abrantes Santos, Eliana Miranda, Gislaine Oliveira Duarte, Guilherme Duffles, Carmino De Souza, Katia B Pagnano

Blood (2024) 144 (Supplement 1): 3157.

https://doi.org/10.1182/blood-2024-208678

Published: 2024

Journal Articles

High Leukemic Stem Cell Frequency in FLT3-Mutated Acute Myeloid Leukemia Patients with Normal Karyotype: Implications for Prognosis

Camila Araújo Bernardino Garcia, Leticia Olops Marini, Mariana Medeiros, Amanda Fernandes Oliveira Costa, Maria Isabel Ayrosa, Katia B Pagnano, Elenaide Nunes, Ana Beatriz F Gloria, Priscila Santos Scheucher, Josiane Lillian Schiavinato, Eduardo M. Rego, Fabiola Traina, Lorena Lobo Figueiredo-Pontes

Blood (2024) 144 (Supplement 1): 6147.

https://doi.org/10.1182/blood-2024-209775

Published: 2024

Journal Articles

Assessment of Additional Chromosomal Abnormalities at Diagnosis in a Cohort of Patients with Chronic Myeloid Leukemia Treated with Generic Imatinib

Gustavo Emmanuel Alves Abrantes Santos, Estela Gasparotto Emiliano, Eliana Miranda, Gislaine Oliveira Duarte, Guilherme Duffles, Natalia Nunes Gonçalves, Gustavo HR Magalhães, Nelma Clementino, Fernanda Salles Seguro, Israel Bendit, Isabella Macedo Toni, Graziele CP Furlin, Maristela Zocca, Rosemary de Oliveira, Paula Melo Campos, Carmino De Souza, Monika Conchon, Katia B Pagnano

Blood (2024) 144 (Supplement 1): 6608.

https://doi.org/10.1182/blood-2024-209997

Published: 2024

Journal Articles

Asciminib in Patients with Chronic Myeloid Leukemia Who Failed Two or More Tyrosine Kinase Inhibitors - Clinical Outcomes from a Managed Access Program in Brazil

Blood (2024) 144 (Supplement 1): 6603.

https://doi.org/10.1182/blood-2024-208360

Published: 2024

Journal Articles

Predictive Value of BCR::ABL1 Transcripts Kinetics in the Molecular Relapse of Chronic Myeloid Leukemia Patients after Tyrosine Kinase Inhibitors Discontinuation: Results from the DES-CML Study

Bruna A Murbach, Gislaine Borba Oliveira, Leonardo Carvalho Palma, Eliana C M CM Miranda, Guilherme D Amarante, Graziele CP Furlin, Isabella Macedo Toni, Carmino De Souza, Lorena Figueiredo-Pontes, Katia B Pagnano

Blood (2023) 142 (Supplement 1): 6371.

https://doi.org/10.1182/blood-2023-190379

Published: 2023

Journal Articles

Real-World Data for FLT3-Mutated Acute Myeloid Leukemia Patients Treated in Resource-Constrained Settings

Wellington F Silva, Fernanda Rodrigues Mendes, Marco Sartori, Maria Isabel A Madeira, Katia B Pagnano, Ana Beatriz F Gloria, Elenaide C. Nunes, Luciana Nardinelli, Rita De Cássia Cavaglieri Medeiros, Israel Bendit, Fabiola Traina, Bruno Kosa Lino Duarte, Lorena Lobo Figueiredo-Pontes, Vanderson Rocha, Elvira Deolinda Rodrigues Pereira Velloso, Eduardo Magalhães Rego

Blood (2023) 142 (Supplement 1): 5839.

https://doi.org/10.1182/blood-2023-187902

Published: 2023

Journal Articles

Feasibility and Relevance of Incorporating Genetic Testing By Next-Generation Sequencing for Acute Myeloid Leukemia Patients Treated in Low- and Middle-Income Countries

Blood (2023) 142 (Supplement 1): 2929.

https://doi.org/10.1182/blood-2023-189806

Published: 2023

Journal Articles

Erythrophagocytosis Mediated By Circulating Monocytes Is Induced By Distinct Mechanisms Depending on the Disease

Marina Dorigatti Borges, Dulcineia Albuquerque, Carolina Lanaro, Sara Teresinha Olalla Saad, Katia B Pagnano, Renata Sesti-Costa, Fernando Ferreira Costa

Blood (2023) 142 (Supplement 1): 2454.

https://doi.org/10.1182/blood-2023-189370

Published: 2023

Journal Articles

Tyrosine Kinase Inhibitor Withdrawal Syndrome in Chronic Myeloid Leukemia Patients Participants of Two Discontinuation Clinical Trials

Bruna A Murbach, Victor H Guidini, Leonardo Carvalho Palma, Eliana C M CM Miranda, Gislaine Borba Oliveira, Guilherme D Amarante, Graziele CP Furlin, Isabella Macedo Toni, Carmino De Souza, Lorena Figueiredo- Pontes, Katia B Pagnano

Blood (2023) 142 (Supplement 1): 6368.

https://doi.org/10.1182/blood-2023-189925

Published: 2023

Journal Articles

A Risk Model for CML Patients with COVID-19: Importance of Molecular Response in the Context of Age, Comorbidities and Country Income

Jerald P. Radich, Chung Hoow Kok, Ekaterina Yu. Chelysheva, Jorge E. Cortes, Qian Jiang, Michael Mauro, Dragana Milojkovic, Beatriz Moiraghi, Franck E. Nicolini, Matilda Ongondi, Katia B Pagnano, Daniela Žácková, Delphine Rea, Nicola Evans, Timothy Hughes

Blood (2022) 140 (Supplement 1): 9617–9619.

https://doi.org/10.1182/blood-2022-165855

Published: 2022

Journal Articles

Five-Year Follow-up of the Phase I/II Discontinuation Trial of Imatinib after Pioglitazone (EDI-PIO) in Chronic Myeloid Leukemia Patients in Deep Molecular Response

Katia B Pagnano, Ana Beatriz Pascoal Lopes, Eliana C M Cristina Martins Miranda, Marcia Delamain, Gislaine B O Duarte, Samuel de Souza Medina, Fernando Vieira Pericole, Guilherme Brasil Duffles Amarante, Bruno K Duarte, Graziele Pavan, Isabella Macedo Toni, Erich V De Paula, Carmino Antonio Souza

Blood (2022) 140 (Supplement 1): 9645–9646.

https://doi.org/10.1182/blood-2022-164598

Published: 2022

Journal Articles

The Prognostic Impact of HMGCLL1 Gene Variant on Treatment Outcomes in Chronic Myeloid Leukemia (CML) Patients: Adverse Impact on the Response, Failure, and Progression with Imatinib Which Can be Abrogated By the Use of 2 nd Generation Tyrosine Kinase Inhibitor (TKI) Upfront Therapy

Blood (2022) 140 (Supplement 1): 6774–6775.

https://doi.org/10.1182/blood-2022-168228

Published: 2022

Journal Articles

Dysregulated Activating and Inhibitory Receptors on Natural Killer Cells Predicts Immune Escape and Poor Outcomes in Acute Myeloid Leukemia

Amanda F O Costa, Valeriya Kuznetsova, Leticia O Marani, Izabela A Lopes, Larissa S Binelli, Priscila S Scheucher, Josiane L Schiavinato, Joana T B Faria, Maria Isabel A Madeira, Katia B Pagnano, Bruno K Duarte, Ana Beatriz F Gloria, Eduardo M Rego, Fabiola Traina, Robert Welner, Lorena L Figueiredo-Pontes

Blood (2022) 140 (Supplement 1): 9113–9114.

https://doi.org/10.1182/blood-2022-168178

Published: 2022

Journal Articles

Serological Response after Two Doses of Sars-Cov-2 Vaccines in CML Patients - a Prospective Study of a Brazilian Center

Ana Carolina Mourão Toreli, Leonardo Fechio, Adriana Silva Santos Duarte, Audrey Basso, Gislaine B O Duarte, Samuel de Souza Medina, Guilherme Brasil Duffles Amarante, Fernando Vieira Pericole, Bruno Deltreggia Benites, Roberto Zulli, Carmino Antonio Souza, Marcelo Addas Carvalho, Katia B Pagnano

Blood (2022) 140 (Supplement 1): 12208–12209.

https://doi.org/10.1182/blood-2022-168108

Published: 2022

Journal Articles

Somatic Mutations Are Frequently Detected in CML Patients before Treatment-Free Remission (TFR) Attempt with Tyrosine Kinase Inhibitor (TKI) Discontinuation but with Uncertain Predictive Value for Tfr Failure

Blood (2022) 140 (Supplement 1): 6782–6783.

https://doi.org/10.1182/blood-2022-167927

Published: 2022

Journal Articles

A Survey Conducted during COVID-19 Pandemic Among Brazilian Chronic Myeloid Leukemia and Philadelphia-Negative Myeloproliferative Neoplasms Patients

Leonardo Fechio, Ana Vitória Ferreira Mota, Jaisson Bortolini, Gislaine B O Duarte, Marcia Delamain, Samuel S Medina, Guilherme Brasil Duffles Amarante, Fernando Vieira Pericole, Hanalydia Machado, Marcelo Addas Carvalho, Katia B Pagnano

Blood (2021) 138 (Supplement 1): 4601.

https://doi.org/10.1182/blood-2021-151168

Published: 2021

Journal Articles

Clinical Significance of Mitochondrial DNA Content in Acute Promyelocytic Leukemia

Antonio R. Lucena-Araujo, Diego A Pereira-Martins, Juan L Coelho-Silva, Isabel Weinhäuser, Pedro Luis Franca-Neto, Douglas RA Silveira, Marinus M Lima, Jan Jacob Schuringa, Luisa C Koury, Raul Antônio Morais Melo, Rosane Bittencourt, Katia B Pagnano, Elenaide C. Nunes, Evandro Maranhão Fagundes, Fabio R. Kerbauy, Lorena Figueredo-Pontes, Eduardo M Rego

Blood (2021) 138 (Supplement 1): 3474.

https://doi.org/10.1182/blood-2021-151265

Published: 2021

Journal Articles

The Importance of Bone Marrow Lymphocyte Subtypes As Predicting Factors for Molecular Recurrence in Patients with Chronic Myeloid Leukemia after Discontinuation of Imatinib

Arthur Gomes Oliveira Braga, Katia B Pagnano, Marina Dal'Bó Pelegrini Campioni, Ana Beatriz P Lopez, Konradin Metze, Gislaine B O Duarte, Irene Lorand-Metze

Blood (2021) 138 (Supplement 1): 2564.

https://doi.org/10.1182/blood-2021-149242

Published: 2021

Journal Articles

Final Results of the Fibromet Trial: An Open Label Phase II Study to Evaluate Metformin Effects on Bone Marrow Fibrosis and Disease Progression in Primary Myelofibrosis Patients

Paula De Melo Campos, Katia B Pagnano, Rubia Isler Mancuso, Fernanda Isabel Della Via, Ângela Condotta Tinoco, Guilherme Rossi Assis-Mendonça, Leandro Luiz Lopes Freitas, Fabiola Traina, Sara T Olalla Saad

Blood (2021) 138 (Supplement 1): 2584.

https://doi.org/10.1182/blood-2021-151077

Published: 2021

NARROW

Immune Content of Mature and Licensed Cytotoxic Cells Is Associated with Treatment-Free Remission in Chronic Myeloid Leukemia

Impact of the 2022 Who Classification on Chronic Myeloid Leukemia

High Leukemic Stem Cell Frequency in FLT3-Mutated Acute Myeloid Leukemia Patients with Normal Karyotype: Implications for Prognosis

Assessment of Additional Chromosomal Abnormalities at Diagnosis in a Cohort of Patients with Chronic Myeloid Leukemia Treated with Generic Imatinib

Asciminib in Patients with Chronic Myeloid Leukemia Who Failed Two or More Tyrosine Kinase Inhibitors - Clinical Outcomes from a Managed Access Program in Brazil

Predictive Value of BCR::ABL1 Transcripts Kinetics in the Molecular Relapse of Chronic Myeloid Leukemia Patients after Tyrosine Kinase Inhibitors Discontinuation: Results from the DES-CML Study

Real-World Data for FLT3-Mutated Acute Myeloid Leukemia Patients Treated in Resource-Constrained Settings

Feasibility and Relevance of Incorporating Genetic Testing By Next-Generation Sequencing for Acute Myeloid Leukemia Patients Treated in Low- and Middle-Income Countries

Erythrophagocytosis Mediated By Circulating Monocytes Is Induced By Distinct Mechanisms Depending on the Disease

Tyrosine Kinase Inhibitor Withdrawal Syndrome in Chronic Myeloid Leukemia Patients Participants of Two Discontinuation Clinical Trials

A Risk Model for CML Patients with COVID-19: Importance of Molecular Response in the Context of Age, Comorbidities and Country Income

Five-Year Follow-up of the Phase I/II Discontinuation Trial of Imatinib after Pioglitazone (EDI-PIO) in Chronic Myeloid Leukemia Patients in Deep Molecular Response

The Prognostic Impact of HMGCLL1 Gene Variant on Treatment Outcomes in Chronic Myeloid Leukemia (CML) Patients: Adverse Impact on the Response, Failure, and Progression with Imatinib Which Can be Abrogated By the Use of 2 nd Generation Tyrosine Kinase Inhibitor (TKI) Upfront Therapy

Dysregulated Activating and Inhibitory Receptors on Natural Killer Cells Predicts Immune Escape and Poor Outcomes in Acute Myeloid Leukemia

Serological Response after Two Doses of Sars-Cov-2 Vaccines in CML Patients - a Prospective Study of a Brazilian Center

Somatic Mutations Are Frequently Detected in CML Patients before Treatment-Free Remission (TFR) Attempt with Tyrosine Kinase Inhibitor (TKI) Discontinuation but with Uncertain Predictive Value for Tfr Failure

A Survey Conducted during COVID-19 Pandemic Among Brazilian Chronic Myeloid Leukemia and Philadelphia-Negative Myeloproliferative Neoplasms Patients

Clinical Significance of Mitochondrial DNA Content in Acute Promyelocytic Leukemia

The Importance of Bone Marrow Lymphocyte Subtypes As Predicting Factors for Molecular Recurrence in Patients with Chronic Myeloid Leukemia after Discontinuation of Imatinib

Final Results of the Fibromet Trial: An Open Label Phase II Study to Evaluate Metformin Effects on Bone Marrow Fibrosis and Disease Progression in Primary Myelofibrosis Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only